Reactive astrocyte nomenclature, definitions, and future directions
By C. Escartin, E. Galea, A. Lakatos, J. O'Callaghan, G. Petzold, A. Serrano‐Pozo, C. Steinhäuser, Andrea Volterra, Giorgio Carmignoto, Amit Agarwal and 71 more. Nature Neuroscience, 2021
1,941 citations recorded by the source corpus.
Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters—preferably in vivo—plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions. Good–bad binary classifications fail to describe reactive astrocytes in CNS disorders. Here, 81 researchers reach consensus on widespread misconceptions and provide definitions and recommendations for future research on reactive astrocytes.
Subfields: Cellular and Molecular Neuroscience, Developmental Neuroscience, Neurology
View Paper: https://www.semanticscholar.org/paper/a3022d571fddad63beb9138c9d897c2d714e57ed
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
Citations in the corpus
- Spinal cord injury: molecular mechanisms and therapeutic interventions (2023, background): “However, the function of these marker genes are not well known,(137) and no experimental evidence proved the A1/A2 astrocytes marker genes exert either toxic or protective functions.(144) Thus, the meaningful definition of reactive astrocytes subtypes should not solely based on the molecular signatu”